MRI and the pathology of breast invasive micropapillary carcinoma

CHUN-HONG HAN1,2, WEI-GEN YAO2, JIE HE1, ZHI-BIN GAO3 and HONG-JIE HU1

1Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016; Departments of 2Radiology and 3Pathology, The Affiliated Yangming Hospital of Ningbo University, Yuyao People’s Hospital, Yuyao, Zhejiang 315400, P.R. China

Received August 22, 2019; Accepted May 5, 2020

DOI: 10.3892/ol.2020.11848

Abstract. Diagnosis of breast invasive micropapillary carcinoma (IMPC) before surgery is of great value for determining the optimal treatment strategy. The aim of the present study was to investigate the magnetic resonance imaging (MRI) and pathological features of IMPC. MRI features of IMPC were characterized in relation to the patients’ clinicopathological features. Clinical manifestations, mammography results and/or MRI findings of patients with IMPC were retrospectively analyzed. Parameters included morphology, plain T2-weighted imaging (T2WI) signal intensity, the apparent diffusion coefficient (ADC), the internal enhancement mode, early enhancement rates and time-intensity curve (TIC) types during dynamic enhanced scanning. A total of 10 lesions were detected by MRI in eight patients, with one case having three lesions with the mean diameter of 34.44 mm. In plain T2WI scanning, the lesions appeared inhomogeneous with a moderate or high signal intensity. When the b value was 800 sec/mm², the average ADC value was 0.823±0.12×10⁻³ mm²/sec. A total of four cases exhibited mass-like enhancement, including an oval rim in one case (three lesions), irregular inhomogeneous enhancement in two cases and irregular uniform enhancement in one case. The margins were clear in one case (three lesions), irregular in two cases and spiculate in one case. Among the four cases with non-mass enhancement, the distribution was focal in two cases, linear in one case and regional in one case, and the internal enhancement mode was cluster-like in one case, heterogeneous in one case and uniform in two cases. The average early enhancement rate was 116.96±45.26%. TICs of type III were observed in all cases. In conclusion, MRI of IMPC demonstrated typical features of malignant tumors and lymphatic vessel infiltration, suggesting that MRI may exhibit guiding significance for the diagnosis and treatment planning of IMPC.

Introduction

Invasive micropapillary carcinoma (IMPC) is a type of mammary epithelial tumor that was added in the 2003 World Health Organization (WHO) classification (1). IMPC was first described by Siriaunkgul and Tavassoli and was reported to account for 0.7‑3% of all breast cancer cases (2). The pathological morphology of IMPC is unique, and immunohistochemistry has demonstrated that the positive portion of the epithelial membrane antigen is located on the outside of the pseudopapillary neoplasm or glandular tube (3). Most cases of IMPC appear mixed with other pathological types of invasive breast carcinoma, most commonly with invasive ductal carcinoma (4).

Lymphatic invasion and lymph node metastasis are common in IMPC, with an incidence of nodal metastases of 24.9%, leading to frequent recurrence and poor prognosis in patients, with a 5-year overall survival rate of 87.5% (5). Even when the proportion of micropapillary structures is <10%, the invasive ability of the cancer is significantly higher compared with that of the same pathological type of breast cancer without IMPC components (6,7). Diagnosis of this cancer type before surgery is of great value for determining the optimal treatment strategy (6), including the choice of surgical methods and the follow-up treatment plan to improve the prognosis of patients.

To date, the majority of studies have focused on the pathological features and ultrasonographic findings of IMPC (8,9). In previous reports, most IMPCs presented as an irregular mass with a high density and a non-circumscribed margin on the mammography, and as an irregular spiculated mass on magnetic resonance imaging (MRI) (10-16). These are typical features of malignant breast cancers (17); however, they are of limited significance for the diagnosis of IMPC. In addition,
only several MRI features were investigated in each study, and thus, the results did not provide enough information for clinical use (10-14). Therefore, the present retrospective study was performed to characterize the MRI and pathological features of IMPC for comprehensive preoperative assessment of IMPC cases.

Patients and methods

Ethics approval. The present study was approved by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Hangzhou, China). All procedures involving human participants were performed in accordance with the ethical standards of the Institutional and/or National Research Committee, the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was waived due to the retrospective nature of the study.

Patients. A total of nine cases of IMPC, confirmed pathologically after surgical resection or ultrasound-guided core-needle breast biopsy at Sir Run Run Shaw Hospital, Zhejiang University School of Medicine between August 2011 and January 2018, were included in the present study. A total of six patients underwent both MRI and mammography, two patients underwent MRI only and one patient underwent mammography only. None of the patients had received radiotherapy or undergone biopsy before MRI examination, and complete immunohistochemical data were available for all lesions.

Imaging. Preoperative mammography was performed in seven cases using a GE Senographe DS digital mammography machine (GE Healthcare) in the routine craniocaudal and mediolateral oblique position.

Preoperative MRI was performed in eight cases with a GE Signa HD Excite 1.5T/HD or 3.0T superconducting MRI scanner (GE Healthcare), with an 8-channel breast phased array surface coil. Patients were in a prone position, and bilateral breasts were hanging naturally in the coil. The plain cross-sectional T2WI fat suppression sequence and fast spin-echo T2WI sequence were scanned at a layer thickness of 4.0 mm with a layer spacing of 1.0 mm. The sagittal T2WI fat suppression sequence was scanned at a layer thickness of 4.0/5.0 mm with a layer spacing of 1.0 mm, a matrix of 512x512 and number of excitations (NEX)2. Diffusion-weighted imaging was performed using single-shot plane echo-planar imaging technology with a matrix of 256x256, layer thickness of 4.0 mm, layer spacing of 1.0 mm, NEX6 and diffusion sensitivity coefficient b values of 0 and 800 sec/mm².

Dynamic enhanced scanning was performed using breast-optimized parallel acquisition of 3D fast gradient echo sequences (volume imaging for breast assessment). The dynamic enhancement was performed before the masking, and 0.2 mmol/kg of the contrast agent Gd-DTPA was injected via a high-pressure syringe through the elbow vein at a rate of 3.0 ml/sec, followed by the injection of 15-20 ml saline. Scanning was performed immediately. A total of seven phases were continuously collected, and the scanning time per phase was 60 sec. Imaging was performed with a reverse angle of 15°, a matrix of 512x512, and NEX2. All patients' dynamic enhanced scans were post-processed on the GE AW4.5 workstation using Functool software (both from GE Healthcare). On each scan, the region of interest (ROI) was selected in the most obvious area of lesion enhancement, avoiding the necrotic cystic region, and the TIC was plotted.

Pathological examination. All IMPC tissue specimens were fixed in 10% neutral formalin for 12 h at room temperature, embedded in paraffin and serially sectioned with a layer thickness of 4 μm. Subsequently, they were stained with hematoxylin for 5 min and eosin for 3 min at room temperature. Immunohistochemical staining was performed using the EnVision (cat. no. K5007; Dako; Agilent Technologies, Inc.) method. Briefly, 4% goat serum (OriGene Technologies, Inc.) was added dropwise for blocking at room temperature for 30 min. Subsequently, different primary antibodies, namely anti-estrogen receptor (ready to use; cat. no. 790-4325; Roche Diagnostics), anti-progesterone receptor (ready to use; cat. no. 790-4296; Roche Diagnostics), anti-human epidermal growth factor receptor 2 (ready to use; cat. no. 790-4493; Roche Diagnostics) and anti-Ki67 (1:800; cat. no. M7240; Dako; Agilent Technologies, Inc.), were added and incubated at room temperature for 2 h. After washing with PBS, one drop of EnVision secondary antibody (ready to use; cat. no. K5007; Dako; Agilent Technologies, Inc.) bound to horseradish peroxidase was added at 37°C for 30 min. All stained sections were observed under a light microscope (magnifications x40 and x100).

Image analysis. All mammography and MRI scans were reviewed by two physicians with >5 years of experience in breast lesion diagnosis, who were blinded to the pathological results. All signs were described in accordance with the 2013 version of the Breast Imaging Reporting and Data System (BI-RADS) proposed by the American College of Radiology (18). The features of mammography included lesion type (only mass, mass with suspected malignant calcification, only suspected malignant calcification, focal asymmetry or structural distortion) and mass characteristics (shape and edge). MRI analysis included determination of the lesion size, plain scanning signal intensity (low, equal and high signal compared with that in normal glands), enhanced lesion morphology, edge morphology, internal enhancement mode, early enhancement rate and the TIC. Lesion size was evaluated using the maximum diameter as the reference index. If multiple lesions were present, the diameter of the largest lesion was measured.

TICs were generated by the post-processing workstation. According to the 2013 BI-RADS, the enhancement rate was based on the first phase enhancement rate as follows: \( \frac{SI_{post} - SI_{pre}}{SI_{pre}} \times 100\% \), where \( SI_{post} \) is the intensity of the first phase signal after lesion enhancement, and \( SI_{pre} \) is the signal intensity before enhanced scanning. The enhancement rate was classified into three modes: Slow (<50%), medium (50-100%) and fast (>100%). The delay period was recorded after the appearance of the peak, with the progressive type recorded as type I, the platform type recorded as type II and the outflow type recorded as type III. For lesions with complicated or non-tumor enhancement, numerous points were repeatedly evaluated, and multiple TICs were considered together.

The ADC map was automatically generated by the workstation and used to artificially measure the ADC value.
A visibly solid part of the lesion was selected, and the ROI was manually selected according to the size of the lesion. The ROI was usually drawn slightly smaller than the lesion range, avoiding the cystic change and hemorrhagic or necrotic areas. ROIs were measured 3-5 times for the calculation of the mean value.

All pathological sections were reviewed by two pathologists with 5 years of experience in the diagnosis of breast diseases, and agreement was achieved through discussion when the diagnoses were inconsistent. According to the 4th edition of the WHO classification of breast tumors published in 2012 (19), IMPC was identified by clusters of cells in a pseudo-papillary structure without a fibrous vascular axis that were surrounded by interstitial spaces. In addition, the examination included the presence of associated ductal carcinoma in situ (DCIS), lymphatic vessel infiltration, axillary lymph node status, proliferation index (Ki-67), and the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Molecular subtype was determined based on ER, PR, HER2 and Ki-67 expression and categorized as follows: Luminal A was ER+ and/or PR+, HER2- and Ki-67-; luminal B was ER+ and/or PR+, HER2- and Ki-67-; luminal-HER2-positive was ER+ and/or PR+ and HER2+; HER2-rich was ER-, PR- and HER2+; and triple negative was ER-, PR- and HER2-.

**Results**

**Clinical characteristics.** All nine patients were female with an average age of 52.11 years (range, 40-65 years). Among them, seven patients were postmenopausal. The initial manifestations were a palpable breast mass in 8 (89%) patients and a gradually enlarged breast mass in two patients. Three patients reported mild tenderness of the mass, and two patients reported ipsilateral breast pain. Eight (80%) lesions were located in the left breast. The initial manifestations, the size of the mass, and the range between the minimum and maximum diameter was 13.2-85.4 mm, with a median value of 18.3 mm. The patient initial manifestation was the left breast (80%, 8/10), which was consistent with the 94% reported by Günhan-Bilgen et al (17). IMPC is a highly invasive type of breast cancer (20). The incidence of IMPC is very low accounting for 0.76-3.8% of breast carcinomas (21-23); however, the degree of malignancy is high. In the present study, the clinical manifestations, pathological changes and imaging results in cases of IMPC were investigated, including mammography and MRI findings. The most common clinical manifestations were palpable breast masses that were presented in 89% (8/9) of the cases studied, and this percentage was slightly lower than compared with the 94% reported by Günhan-Bilgen et al (17). Among the observed lesions, the site with the most frequent IMPC occurrence was the left breast (80%, 8/10), which was consistent with the finding of 60.5% of lesions (23/38) in the left breast reported by Kim et al (24). In most cases, axillary lymph node metastasis was present at the time of diagnosis, and axillary lymphadenopathy was noticed before the primary tumor was identified in one case of the present study.

The mammography results of all patients in the present study suggested malignant tumors, and the characteristics
Table I. Clinical characteristics of the patients.

| Patient no. | Age, years | Menopause | Symptoms and physical examination findings | Stage and molecular type |
|-------------|------------|-----------|-------------------------------------------|--------------------------|
| 1           | 52         | +         | A mass in the right upper quadrant of the breast was occasionally noticed, starting 302 days previously. PE: Mass in the right breast at 10 o'clock and 2.5 cm from the nipple, 1.8x1.5 cm, hard, with uneven surface, unclear edge, and dimple sign (+). | pT1N0M0/luminal B         |
| 2           | 50         | +         | A mass was detected by mammography 33 days previously. PE: Mass in the upper left quadrant of the left breast, 1.5 cm in diameter, hard, with unclear edge. | pT1N1M0/luminal B         |
| 3           | 65         | +         | Two years previously, a mass was inadvertently discovered by touch, which gradually increased in size. The patient reported pain in the left breast, discomfort and itchy skin on the surface, with local ulceration 1 month previously. PE: Mass in the left breast at 3 o'clock, 4x3 cm, hard, with unclear boundary and unmovable. | ypT2N2M0/luminal A        |
| 4           | 50         | +         | A mass in the left breast was discovered by self-examination, with slight tenderness to touch. PE: Mass of medium texture in the left breast at 12 o'clock, 3 cm away from the areola, 1.5x1.5 cm, with unclear edge and dimple sign (+). | pT1N1M0/luminal B         |
| 5           | 51         | +         | A mass was occasionally felt, starting 35 days previously. PE: Mass in the upper outer quadrant of the left breast at 1-3 o'clock, 7x5 cm, hard, with unclear boundary and unmovable. | ypT4N2M0/luminal-HER2     |
| 6           | 60         | +         | One lesion was discovered by self-examination that was painful, but tolerable and without periodicity. PE: Two masses in the left breast at 3 o'clock, 2 and 3 cm away from the areola, respectively, 2x1.5 and 1x1 cm, respectively, moderate, with unclear boundary and movable. | pT1N1M0/luminal A         |
| 7           | 48         | -         | One lesion was discovered by self-examination 123 days previously, with tenderness, which became larger in the past 0.5 month. PE: Mass in the right breast at 2 o'clock, 4 cm outside the areola, 2x2 cm, hard, clear, with smooth surface and not easy to push. | pT1N0M0/luminal A         |
| 8           | 40         | -         | A left axillary mass was discovered by self-examination due to discomfort at the left axillary, starting 14 days previously. PE: Left axillary discomfort, mass in the left breast at 1-2 o'clock, 1x1 cm, hard, with unclear boundary, general activity, and a second left axillary mass, 2x1 cm, hard, with general activity. | pT1N3M0/luminal B         |
| 9           | 53         | +         | A mass was inadvertently felt by palpation in the left breast with local tenderness 32 days previously. PE: Local tenderness of a mass in the left breast at 6 o'clock, 1.5x1 cm, hard, with unclear boundary, poor activity and suspicious dimple sign. | pT1N1M0/luminal-HER2      |

PE, physical examination; HER2, human epidermal growth factor receptor 2.
Table II. Mammography, MRI and pathological characteristics of 9 cases of IMPC.

| Patient no. | Diameter, mm | Mammography | ADC of MRI, x10⁻³ mm²/sec | Pathology | Immunohistochemistry |
|-------------|--------------|-------------|----------------------------|-----------|---------------------|
| 1           | 13.2         | High density, irregular shape, burr edge | 0.681 | - | - | - | ER⁺, PR⁻, Her-2⁻, Ki-67 (30%) |
| 2           | 19.2         | N/A         | 0.882 | - | + | - | ER⁺, PR⁺, Her-2⁻, Ki-67 (30%) |
| 3           | 64.2 (largest of 3 lesions) | High density, lobulated, unclear edge, thickened adjacent skin, depression | 0.613 | + | + | - | ER⁺, PR⁺, Her-2⁻, Ki-67 (10%), no HER2 amplification FISH |
| 4           | 15           | High density, irregular shape, blurry edges | 0.849 | - | + | + | ER⁺, PR⁺, Her-2⁻, Ki-67 (15%) |
| 5           | 85.4         | Large pieces of asymmetrical and dense lesions, with regional distribution of fine pleomorphic calcification, thickened local skin, nipple retraction | 0.989 | + | + | - | ER⁺, PR⁺, Her-2⁻, Ki-67 (70-80%), HER2 amplification on FISH |
| 6           | 44.9         | High density, irregular shape, burr edge, visible fine calcification of the segmental distribution | 0.838 | - | + | + | ER⁺, PR⁺, Her-2⁻, Ki-67 (10%) |
| 7           | 16.2         | N/A         | 0.778 | - | - | + | ER⁺, PR⁺, Her-2⁻, Ki-67 (10%) |
| 8           | 17.4         | Under the left armpit, increased density, unclear edges, several lymph nodes displayed around | 0.955 | + | + | - | ER⁺, PR⁺, Her-2⁻, Ki-67 (20%), no HER2 amplification on FISH |
| 9           | 27.7         | High density, irregular shape, unclear edge, small pleomorphic calcification around the segment, thickening near the local areola skin | N/A | - | + | - | ER⁺, PR⁺, Her-2⁻, Ki-67 (20%) |

MRI, magnetic resonance imaging; IMPC, invasive micropapillary carcinoma; ADC, apparent diffusion coefficient; LVI, lymphovascular invasion; LNM, lymph node metastasis; IC, intraductal cancer; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; FISH, fluorescence in situ hybridization; N/A, not applicable.
were mostly consistent with those observed in the literature (17,25-28), including a mass (54.2-74.4%), irregular high density and microcalcification (38.5-66.7%). In the study by Lim et al (13), microcalcification was observed around the edge of the mass. As reported by Adrada et al (10) and Alsharif et al (12), the common morphological features of microcalcification were polymorphism (57%, 11/19) and polymorphism or fine branch morphology (86.7%, 13/15).

Figure 1. Scans from a 51-year-old female patient. (A) A mass with irregular shape, (B) spiculation and (C) heterogeneous enhancement was observed in the left upper quadrant of the breast by enhanced magnetic resonance imaging. (D) The early enhancement rate was 20.3%, and the time-intensity curve was of type III. (E) The observed diffusion coefficient value was 0.849x10^{-3} mm²/sec. The invasive micropapillary carcinoma was surrounded by a non-mass enhancement lesion with segmental distribution and an internal cluster-like enhanced region, which was pathologically confirmed as simultaneous ductal carcinoma in situ. (F and G) Mammography revealed a slightly dense mass with an irregular shape and spiculation.

Figure 2. Scans from a 51-year-old female patient. (A) A non-mass enhancement lesion with (B) a regional distribution and (C) an internal cluster-like enhancement was observed in the left upper quadrant of the breast by enhanced magnetic resonance imaging. (D) The early enhancement rate was 110.3%, and the time-intensity curve was of type III. (E) The observed diffusion coefficient value was 0.898x10^{-3} mm²/sec. The invasive micropapillary carcinoma was accompanied by (A) thickening of the left areola skin, nipple retraction, and (B) multiple lymph nodes in the left axillary fossa. (F and G) Mammography revealed a large mass with asymmetric density in the left breast, extending beyond one quadrant, with a regional distribution of small polymorphic calcification, local skin thickening, nipple retraction and axillary lymph node enlargement.

Microcalcification is the most common mammographic feature of DCIS (29), and these imaging features are highly suggestive of malignant tumors.

Previous studies have reported that IMPC exhibits an irregular mass with an irregular or spiculated edge on MRI (10,13). The enhanced scanning curve is outflow-type and the internal enhancement mode is very different, with 16.7-38.9% probability of surrounding non-mass-enhanced lesions (10-14).
Secondly, 22-39% of cases presented with non-mass enhancement in these studies (10-14). Kubota et al (15) compared the MRI features of eight IMPC lesions and 22 invasive ductal carcinomas and demonstrated that IMPC was more likely to exhibit a characteristic irregular mass. In the present study, 50% of IMPC cases exhibited mass-like enhancement, and the other 50% exhibited non-mass enhancement. The incidence of non-mass enhancement was higher compared with that reported in the literature, which was possibly due to the increase of the pathological micro-nipple component. This needs to be confirmed by analysis of more cases. Among the four cases of mass-like enhanced lesions and the four cases of non-mass enhanced lesions, one case in each set had non-mass enhancement of segmental distribution, which was pathologically confirmed to be accompanied by DCIS. In the four lesions with non-mass enhancement, two cases had a focal distribution, one case had a linear distribution and one case had a regional distribution, which differed from previous reports. Yun et al (11) reported seven cases with segmental distribution, and Jones et al (14) reported that most lesions with non-mass enhancement had a diffuse distribution. The internal enhancement patterns in the present study also differed, and TICs were of type III in all cases, which was consistent with a previous study (14). In addition, the ADC with a b value of 800 sec/mm² was determined, and a mean ADC value of 0.823±0.12x10⁻³ mm²/sec was observed, which indicated malignant tumors (16). The enhancement rate in the first phase was mostly the rapid enhancement mode (75%, 6/8) according to the 2013 version of the BI-RADS (19), and the average was 116.96±45.26%. Although the standard deviation for the mean enhancement rate was large, the early rapid enhancement mode also suggested the differentiation of malignant tumors. MRI demonstrated higher sensitivity for lesion detection compared with that of mammography, especially for the detection of lesions with non-mass enhancement and for precise definition of the lesion (13,14). Kubota et al (15) concluded that radiography, including MRI, can be carefully interpreted to determine the boundary of the lesion, and additional resection can be performed at the positive edge (cells close to the edge of the previously resected specimen).

Previous studies have reported that IMPC is often associated with DCIS, with an incidence as high as 78.6% (10,13,25). Among the patients in the present study, only three cases (33%) had IMPC mixed with DCIS, and the incidence was lower than previously reported. The rate of axillary lymph node metastasis in IMPC has been reported to range between 56 and 90.5% (12-14,26,27), and lymphatic vascular invasion has been demonstrated to be an independent factor for poor prognosis and a marker of lymph node metastasis (4,24). Zekioglu et al (4) observed lymphatic invasion in 75% of cases of IMPC, of which 82% exhibited lymph node metastasis. In the present study, lymphatic invasion was identified in three cases (33.3%, 3/9), whereas axillary lymph node metastasis was observed in seven cases (77.8%, 7/9). The longest lesion diameter in a case with lymphatic infiltration and simultaneous intravascular tumor thrombus lesions was 17.4 mm, and the initial clinical manifestation was palpable axillary lymphadenopathy, indicating that the size of IMPC was not directly related to tumor invasion and histological characteristics, including histological grade; thus, lymphatic vessel density and lymphocytic infiltration of IMPC may be more relevant than lesion size (28). MRI revealed that three cases (37.5%, 3/8) had axillary lymph node metastasis. The sensitivity, specificity, positive predictive value, negative predictive value and overall accuracy of MRI for axillary lymph node metastasis diagnosis were 50, 100, 100, 40 and 62.5%, respectively. These results suggested that the possibility of axillary lymph node metastasis in patients with IMPC was high regardless of

---

**Table III. MRI characteristics of pure breast IMPC.**

| Features                        | n (%)          |
|---------------------------------|----------------|
| Mass-like enhancement           | 4              |
| Shape                           |                |
| Oval                            | 4 (25)         |
| Irregular shape                 | 3 (75)         |
| Edge                            |                |
| Clear                           | 2 (50)         |
| Irregular                       | 1 (25)         |
| Burr                            | 1 (25)         |
| Internal enhancement feature    |                |
| Uniform                         | 1 (25)         |
| Inhomogeneous                   | 2 (50)         |
| Edge enhancement                | 1 (25)         |
| Non-mass enhancement            | 4              |
| Distribution                    |                |
| Linear                          | 1 (25)         |
| Focal                           | 2 (50)         |
| Regional                        | 1 (25)         |
| Internal enhancement feature    |                |
| Uniform                         | 2 (50)         |
| Inhomogeneous                   | 1 (25)         |
| Cluster-like                    | 1 (25)         |
| TIC                             | 8              |
| Early stage                     |                |
| Slow                            | 1 (12.5)       |
| Medium                          | 1 (12.5)       |
| Fast                            | 6 (75)         |
| Delay stage                     |                |
| Outflow type                    | 8 (100)        |
| Axillary lymph node metastasis  |                |
| (+) on MRI                      | 6              |
| (-) on MRI                      | 3 (50)         |
| Metastatic lymph nodes detected by MRI | 3 (50) |
| Sensitivity                     | 8              |
| Specificity                     | 50%            |
| Positive predictive value       | 100%           |
| Negative predictive value       | 100%           |
| Overall accuracy                | 40%            |
| Invasion of the nipple, chest wall or skin | 2 (25) |

MRI, magnetic resonance imaging; IMPC, invasive micropapillary carcinoma; TIC, time-intensity curve.
the MRI findings, and pathological examination of lymphatic vessels and regional lymph nodes was needed.

The molecular phenotype of lesions in the present study was mainly luminal type (78%, 7/9), and no cases were triple negative, which was similar to the findings presented in previous reports (4,11). Positivity for hormone receptors is usually observed in better differentiated tumors, and the prognosis is better in these cases. This seems to contrast with the high rates of biological invasion and recurrence and poor prognosis in IMPC. It is speculated that IMPC has unique histological features. In the present study, 2 cases (22%, 2/9) were luminal-HER2 positive, and this frequency of HER2-positive cases was lower than those previously reported (4,10,11). Previous studies have confirmed that HER2 gene amplification and/or upregulation of HER2 protein expression is associated with poor prognosis in patients with invasive breast cancer (26,30). In the present study, one patient with the luminal-HER2-positive type presented with metastasis to the ipsilateral chest wall 2 years after treatment with chemoradiotherapy, modified radical mastectomy and endocrine therapy. After changing the chemotherapy regimen, multiple liver, lung and contralateral breast cancer metastases were observed. Retrospective analysis of the molecular phenotype in this case, in addition to HER2+ and HER2 gene amplification by fluorescence in situ hybridization and Ki-67 index measurement (~70-80%, indicating a high cell proliferation index), indicated accelerated tumor metastasis. In the present study, the negative predictive value of MRI for axillary lymph node metastasis was only 40%, indicating that regardless of the clinical and imaging findings for lymph nodes, patients with IMPC should undergo biopsy of the axillary lymph nodes.

Complete surgical resection of the lesion is an important therapy in IMPC (5). However, IMPC is typically irregular in shape on MRI and the border is unclear (8,10). Thus, the possibility of residual cancer cells remaining in the breast after breast-conserving surgery is high. If a rapid pathological analysis performed during surgery reveals the presence of cancer cells at the margin of the resected specimen, re-expansion of the resection is required, and a prolonged operative time and re-expanded resection increase the probability of postoperative complications.

The present study had several limitations. First, the sample size was small, and more cases are needed. Second, the study was a retrospective analysis, and not all patients underwent both mammography and MRI examinations. Third, pathology was not classified according to the WHO guidelines. A multicenter study is the next step to expand the sample size and compare the MRI features, pathological grades and molecular phenotypes to identify effective imaging features for preoperative evaluation and prognosis prediction.

In conclusion, the MRI features of IMPC included typical malignant tumor characteristics with ready invasion of lymphatic vessels. Among the IMPC cases presented, frequent nodal metastases and high likelihood of luminal type lesions were observed. These characteristics provide valuable insight for the diagnosis of IMPC.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
CHH and JH contributed to the experiments and data analysis, and wrote the manuscript. ZBG provided pathological assistance. WGY and HJ contributed to the analysis and the interpretation of the data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (Hangzhou, China). All procedures involving human participants were performed in accordance with the ethical standards of the Institutional and/or National Research Committee, the 1964 Helsinki Declaration and its later amendments. All data published here are under the consent for publication.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Tavassoli FA and Devilee P: Pathology and genetics of tumors of the breast and female genital organs. World Health Organization classification of tumors. IARC Press, 2003.
2. Siriaunkgul S and Tavassoli FA: Invasive micropapillary carcinoma of the breast. Mod Pathol 6: 660-662, 1993.
3. Luna-More S, Gonzalez B, Acero C, Rodrigo I and Luna C: Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol Res Pract 190: 668-674, 1994.
4. Zekioglu O, Erhan Y, Ciris M, Bayramoglu H and Ozdemir N: Invasive micropapillary carcinoma of the breast: High incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma. Histopathology 44: 18-23, 2004.
5. Lewis GD, Xing Y, Haque W, Patel T, Schwartz M, Chen A, Farach A, Hatch S, Butler EB, Chang J and Teh BS: Prognosis of lymphotrophic invasive micropapillary breast carcinoma analyzed by using data from the national cancer database. Cancer Commun (Lond) 39: 60, 2019.
6. Li W, Han Y, Wang C, Guo X, Shen B, Liu F, Jiang C, Li Y, Yang Y, Lang R, et al: Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast: A 12-year prospective clinical study. Mod Pathol 31: 956-964, 2018.
7. Kaya C, Uçak E, Bozkurt E, Ömeroğlu S, Kartal K, Yazar P, Idiz UO and Mihmanli M: The impact of micropapillary component ratio on the prognosis of patients with invasive micropapillary breast carcinoma. J Invest Surg: 1-9, 2018.
8. Kamitani K, Kamitani T, Ono M, Toyoshima S and Mitsuyama S: Ultrasonographic findings of invasive micropapillary carcinoma of the breast: Correlation between internal echogenicity and histological findings. Breast Cancer 19: 349-352, 2012.

9. Mizushima Y, Yamaguchi R, Yokoyama T, Ogo E and Nakashima O: Recurrence of invasive micropapillary carcinoma of the breast with different ultrasound features according to lesion site: Case report. Kurume Med J 58: 81-85, 2011.

10. Adrada B, Arribas E, Gilcreese M and Yang WT: Invasive micropapillary carcinoma of the breast: Mammographic, sonographic, and MRI features. AJR Am J Roentgenol 193: W58-W63, 2009.

11. Yun SU, Choi BB, Shu KS, Kim SM, Seo YD, Lee JS and Chang ES: Imaging findings of invasive micropapillary carcinoma of the breast. J Breast Cancer 15: 57-64, 2012.

12. Alsharif S, Daghistani R, Kamberoglu EA, Omeroglu A, Meterissian S and Mesurolle B: Mammographic, sonographic and MR imaging features of invasive micropapillary breast cancer. Eur J Radiol 83: 1375-1380, 2014.

13. Lim HS, Kuzmiak CM, Jeong SI, Choi YR, Kim JW, Lee JS and Park MH: Invasive micropapillary carcinoma of the breast: MR imaging findings. Korean J Radiol 14: 551-558, 2013.

14. Jones KN, Guimaraes LS, Reynolds CA, Ghosh K, Degrin AC and Glazebrook KN: Invasive micropapillary carcinoma of the breast: Imaging features with clinical and pathologic correlation. AJR Am J Roentgenol 200: 689-695, 2013.

15. Kubota K, Ogawa Y, Nishioka A, Murata Y, Itoh S, Hamada N, Morio K, Maeda H and Tanaka Y: Radiological imaging features of invasive micropapillary carcinoma of the breast and axillary lymph nodes. Oncol Rep 20: 1143-1147, 2008.

16. Peng YX, Cai HM and CY C: Vulation the differential value of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance in breast lesions. Chinese Journal 11: 1-4, 2014.

17. G"unhan-Bilgen I, Zekioglu O, Ust"un EE, Memis A and Erhan Y: Invasive micropapillary carcinoma of the breast: Clinical, mammographic, and sonographic findings with histopathologic correlation. AJR Am J Roentgenol 179: 927-931, 2002.

18. Allarakha A, Gao Y, Jiang H and Wang PF: Prediction and prognosis of biologically aggressive breast cancers by the combination of DWI/DCE-MRI and immunohistochemical tumor markers. Discov Med 27: 7-15, 2019.

19. American College of Radiology, Breast Imaging Reporting and Data System (BI-RADS). 4th Edition, American College of Radiology, Reston, 563-570, 2013.

20. Onder S, Fayda M, Karanlik H, Bayram A, "Sen F, Cabioglu N, Tuzlali S, Ilhan K and Yavuz E: Loss of ARID1A expression is associated with poor prognosis in invasive micropapillary carcinomas of the breast: A clinicopathologic and immunohistochemical study with long-term survival analysis. Breast J 23: 638-646, 2017.

21. Shi WB, Yang LJ, Hu X, Zhou J, Zhang Q and Shao ZM: Clinico-pathological features and prognosis of invasive micropapillary carcinoma compared to invasive ductal carcinoma: A population-based study from China. PLoS One 9: e101590, 2014.

22. Gokce H, Durak MG, Akin MM, Canda Y, Balei P, Ellidokuz H, Demirkan B, Gorken IB, Sevîc AI, Kocod MA, et al: Invasive micropapillary carcinoma of the breast: A clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma. Breast J 19: 374-381, 2013.

23. Hashmi AA, Aijaz S, Mahboob R, Khan SM, Irfan M, Iftikhar N, Nisar M, Siddiqui M, Edhi MM, Faridi N and Khan A: Clinicopathologic features of invasive micropapillary and microcystic breast carcinoma: Comparison with invasive ductal carcinoma of breast. BMC Res Notes 11: 531, 2018.

24. Kim MJ, Gong G, Joo HJ, Ahn SH and Ro JY: Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component. Arch Pathol Lab Med 129: 1277-1282, 2005.

25. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, PusztaI L and Bloom KJ: The her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 8: 307-325, 2003.

26. Kuroda H, Sakamoto G, Ohnisi K and Itoyama S: Clinical and pathologic features of invasive micropapillary carcinoma. Breast Cancer 11: 169-174, 2004.

27. Nassar H, Wallis T, Andea A, Dey J, Adsay V and Visscher D: Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol 14: 836-841, 2001.

28. Guo X, Chen L, Lang R, Fan Y, Zhang X and Fu L: Invasive micropapillary carcinoma of the breast: Association of pathologic features with lymph node metastasis. Am J Clin Pathol 126: 740-746, 2006.

29. Evans A, Spinner S, Wilson R, Sibbering M, Poller D, Elston C and Ellis I: Ductal carcinoma in situ of the breast: Correlation between mammographic and pathologic findings. AJR Am J Roentgenol 162: 1307-1311, 1994.

30. Ferretti G, Felici A, Papaldo F, Fabi A and Cognetti F: HER2/neu role in breast cancer: From a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19: 56-62, 2007.